In vitro activation of macrophages, monocytes, and dendritic cells [26–30]. | |
In vivo administration activates monocyte at low doses in clinical studies [31–33]. | |
Increases antigen processing and presentation by Macrophages [34–36]. | |
Enhanced in vitro tumoricidal activity of PBMC for human melanoma cells [26]. | |
Induces macrophage production of an angiogenesis inhibitor [37, 38]. |